Abstract #0087

Cost Effectiveness of MRI Before Prostate Biopsy

Shivani Pahwa¹, Nicholas Schiltz², Lee Ponsky³, Ziang Lu¹, Sara Dastmalchian¹, Robert Abouassaly³, Mark Griswold⁴, and Vikas Gulani⁵

¹Radiology, Case Western Reserve University, Cleveland, OH, United States, ²Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, United States, ³Urology, Case Western Reserve University, Cleveland, OH, United States, ⁴Radiology and Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States, ⁵Radiology, University Hospitals Case Medical Center, Cleveland, OH, United States

The perception that MRI inflates health care costs impedes its incorporation into prostate cancer treatment algorithms, despite robust evidence of its accuracy. We evaluated the cost effectiveness of 13 different strategies using a decision tree model in which MRI is performed before non-targeted, transrectal ultrasound guided prostate (TRUS) biopsy. Our results show that MRI is cost effective in each of these strategies, and also adds incremental quality adjusted life years (QALY) to the patient over and above the standard practice of performing non-targeted TRUS biopsy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here